Tianjin Chase Sun Pharmaceutical Co., LTD   Report issue

For profit Phase 2 Phase 4
Founded: Tianjin China (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2014
NCT02219971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Tianjin Chasesun Pharmaceutical Co., LTD

Active Ingredients

Drugs in Phase 4 Trials (1)

xuebijing (1 trial)

Drugs in Phase 2 Trials (2)

IMMH-010 (1 trial)

kukoamine b (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Sepsis (Phase 4)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 3